Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session: Non-metastatic NSCLC and other thoracic malignancies

LBA48 - Community-based mass screening with low-dose CT for lung cancer in Guangzhou

Date

11 Sep 2022

Session

Proffered Paper session: Non-metastatic NSCLC and other thoracic malignancies

Topics

Population Risk Factor;  Clinical Research;  Secondary Prevention/Screening

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Wenhua Liang

Citation

Annals of Oncology (2022) 33 (suppl_7): S808-S869. 10.1016/annonc/annonc1089

Authors

W. Liang1, C.C. Li2, J. Li1, S. Xiong1, B. Cheng2, H. Liang2, N. Zhong3, J. He4

Author affiliations

  • 1 Thoracic Oncology Dept., The First Affiliated Hospital of Guangzhou Medical University, 510120 - Guangzhou/CN
  • 2 Thoracic Oncology Dept., The First Affiliated Hospital of Guangzhou Medical University, 510000 - Guangzhou/CN
  • 3 Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, 510230 - Guangzhou/CN
  • 4 Thoracic Oncology Dept., The First Affiliated Hospital of Guangzhou Medical University, 510230 - Guangzhou/CN
More

Resources

Login to access the resources on OncologyPRO.

Abstract LBA48

Background

This study aimed to investigate an approach for lung cancer (LC) screening in the general population and develop a risk prediction model to improve risk assessment.

Methods

This project is a community-based mass screening with LDCT for the early detection of LC. Participants were enrolled and screened from 2015 to 2021. Eligible subjects were between 40 and 74 years of age among the residents from four communities in Guangzhou, while exclusion criteria were persons diagnosed with LC within the past 5 years. A questionnaire including detailed demographic data and health conditions was used. Binary logistic regression analysis was used to screen potential risk factors. A multivariate model was built based on the participant characteristics combined with carcinoembryonic antigen (CEA) at a cutoff of 3.9. Model discrimination was evaluated by the area under the curve (AUC).

Results

11,708 participants were screened, comprising 5,452 males and 6,256 females with a median age of 59 (IQR, 51-65) years. 189 (1.6%) LCs were diagnosed, among which 162 (85.7%) cases were in stage 0-I. Only 37 (19.6%) and 105 (55.6%) of diagnosed cases met the criteria per NCCN and Chinese screening guidelines, respectively. We found seven independent risk/protective factors for LC through multivariate adjustment (Table). Using these variables combined with CEA, the model presented an AUC of 0.71 (95%CI, 0.67-0.75), which was significantly higher than that of guidelines in NCCN (0.52, 95%CI 0.50-0.55) and China (0.62 95%CI 0.58-0.67), respectively. Stratified analysis by smoking and stages showed that the AUCs were higher among smokers (0.77, 95%CI 0.71-0.83) and stage I to IV LC (0.74, 95%CI 0.70-0.78, excluding MIA) than in non-smokers (0.69, 95%CI 0.64-0.74) and preinvasive diseases (AIS and MIA, 0.64, 95%CI 0.57-0.72), respectively. Table: 000LBA48

Factor OR (95% CI) P value
Personal cancer history 6.03 (4.02-9.02) <0.001
Exposure to silicon dioxide 5.22 (1.13-24.1) 0.034
Age
50-59 vs. 40-49 1.50 (0.82-2.76) 0.188
60-74 vs. 40-49 2.27 (1.26-4.09) 0.006
Food allergy 2.58 (1.33-5.02) 0.005
History of asthma 2.32 (1.31-4.13) 0.004
Family history of cancer
Lung cancer 1.58 (1.04-2.40) 0.033
Other cancer 1.12 (0.77-1.64) 0.549
Allergy to temperature change 0.46 (0.28-0.77) 0.003

Conclusions

Mass screening with LDCT can identify early-stage LC in Guangzhou, and a risk prediction model based on participant characteristics combined with CEA improves LC risk assessment.

Clinical trial identification

NCT04938804.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Guangzhou Municipal Party Committee and Municipal Government and Guangzhou Municipal Health Commission.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.